Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:49 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control
NCT00713947 · Assistance Publique - Hôpitaux de Paris · PHASE4 · withdrawn · last registry update 2026-03-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “no inclusion” | – | Registry record, Assistance Publique - Hôpitaux de Paris |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ATP4A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-15Phase 3 first posted: Onconic Therapeutics Inc., JP-1366 20 mg, Lansoprazole 30 mg Placebo, Clarithromycin 500mg, Amoxicillin 1000mg + Lansoprazole 30mg, JP-1366 20 mg Placebo, Clarithromycin 500mg, Amoxicillin 1000mg (NCT07875933)
- 2026-09-10Results posted on the registry: Duke University, PPI deprescribing (NCT05070351)
- 2026-09-09Phase 3 first posted: Reham Abdelkader Elkhouly, Bismuth added on triple therapy + Quadruple therapy (NCT07810985)
- 2026-09-09Also stopped (terminated): Eli Lilly and Company, LY4100511 + Rabeprazole (NCT06916143)
- 2026-08-24Results posted on the registry: Universitas Indonesia, Fexuprazan + Esomeprazole (NCT07326904)
- 2026-08-21Also stopped (terminated): Genentech, Inc., GDC-0587 + Giredestrant (NCT07214662)
- 2026-08-07Phase 3 first posted: Phathom Pharmaceuticals, Inc., Vonoprazan + Placebo (NCT07752407)
- 2026-08-05Phase 3 first posted: Daewoong Pharmaceutical Co. LTD., DWP14012 20mg + DWP14012 20 mg placebo (NCT07746518)
- 2026-08-04Also stopped (withdrawn): Shanghai Zhongshan Hospital, Esomeprazole + Bismuth potassium citrate (NCT05250050)
- 2026-08-03Also stopped (terminated): Biao Zou, FMT + Conventional drugs (NCT05753774)
- 2026-07-28Phase 3 first posted: Daewoong Pharmaceutical Co. LTD., DWP14012 40mg (Fexuprazan) + Lansoprazole 30mg (NCT07730138)
- 2026-07-28Phase 3 first posted: Onconic Therapeutics Inc., JP-1366 10 mg + Lansoprazole 15mg (NCT07732075)
- 2026-07-07Phase 3 first posted: Hanyang University Guri Hospital, Tegoprazan 50 mg + Placebo (NCT07687706)
- 2026-06-15Also stopped (terminated): Pfizer, Full dose Pantoprazole plus matching placebo + Half Dose Pantoprazole plus matching placebo (NCT04821310)
- 2026-06-09Also stopped (withdrawn): Spital Limmattal Schlieren, a drug against ATP4A (NCT04423588)
- 2026-06-04Results posted on the registry: Children's Mercy Hospital Kansas City, Lansoprazole + Pantoprazole (NCT04248335)
- 2026-06-01Also stopped (terminated): University of Oklahoma, Omeprazole (NCT04930991)
- 2026-05-29Results posted on the registry: Eli Lilly and Company, LY3502970 + Esomeprazole (NCT05051566)
- 2026-05-28Also stopped (withdrawn): Cinclus Pharma Holding AB, Linaprazan glurate - High dose + Linaprazan glurate - Low dose (NCT07313774)
- 2026-05-27Phase 3 first posted: King George's Medical University, Vonoprazan + Rabeprazol (NCT07608536)
- 2026-05-26Phase 3 first posted: Xuanzhu Biopharmaceutical Co., Ltd., Anaprazole Sodium enteric-coated tablet + Esomeprazole magnesium enteric-coated tablets (NCT07606833)
- 2026-05-08Phase 3 first posted: National Taiwan University Hospital, Bismuth Add-on to Vonoprazan Dual Therapy + Vonoprazan dual therapy (NCT07576959)
- 2026-05-06Also stopped (terminated): Takeda, Dexlansoprazole (NCT02615184)
- 2026-04-15Results posted on the registry: Boehringer Ingelheim, Midazolam + Warfarin (NCT02783040)
- 2026-03-23Phase 3 first posted: Beni-Suef University, BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE (NCT07487142)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision